These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10926083)

  • 21. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 23. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
    Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined androgen blockade.
    Crawford ED
    Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
    Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
    World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current topics and perspectives relating to hormone therapy for prostate cancer.
    Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
    Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal therapy: historical perspective to future directions.
    Mcleod DG
    Urology; 2003 Feb; 61(2 Suppl 1):3-7. PubMed ID: 12667881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of combined androgen blockade for advanced prostate cancer in British Columbia.
    Chau A; de Lemos ML; Pickles T; Blood P; Kovacic L; Abadi S; Barnett J
    J Oncol Pharm Pract; 2010 Jun; 16(2):121-6. PubMed ID: 19541764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormonal therapy of prostatic cancer: current status of the problem].
    Veliev EI; Okhrits VE
    Urologiia; 2011; (4):64-8. PubMed ID: 22066246
    [No Abstract]   [Full Text] [Related]  

  • 33. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteinizing hormone-releasing hormone monotherapy: a viable option for treatment of prostate cancer?
    Schellhammer PF
    Urology; 2001 Aug; 58(2 Suppl 1):10-5. PubMed ID: 11502437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Akaza H
    Cancer Sci; 2011 Jan; 102(1):51-6. PubMed ID: 21091846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving role of hormone therapy in advanced prostate cancer.
    Dreicer R
    Cleve Clin J Med; 2000 Oct; 67(10):720-2, 725-6. PubMed ID: 11060958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controversies surrounding androgen deprivation for prostate cancer.
    Patterson SG; Balducci L; Pow-Sang JM
    Cancer Control; 2002; 9(4):315-25. PubMed ID: 12228757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
    Harv Mens Health Watch; 1999 Dec; 4(5):5-8. PubMed ID: 10564905
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].
    Vojinov S; Levakov I; Jeremić D; Zivojinov S; Marusić G
    Vojnosanit Pregl; 2011 Apr; 68(4):321-6. PubMed ID: 21630520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.